Evidence map›Paper›PMID 30659902›Full record

ArticleUrology2020

Ex-vivo Imaging of Upper Tract Urothelial Carcinoma Using Novel pH Low Insertion Peptide (Variant 3), a Molecular Imaging Probe.

Joseph Brito, Borivoj Golijanin, Ohad Kott, Anna Moshnikova, Catrina Mueller-Leonhard, Boris Gershman, Oleg A Andreev, Yana K Reshetnyak, Ali Amin, Dragan Golijanin

Abstract read
In one paragraph

Article in Urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Frontiers in oncology · 2023
    Article
  5. Increasing the Realism ofJournal of chemical theory and computation · 2022
    Article
  6. Article
  7. Article
  8. Frontiers in oncology · 2022
    Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joseph BritoUrology Department, Yale University School of Medicine, New Haven, CT.
Borivoj GolijaninDepartment of Pathology & Laboratory Medicine, The Warren Alpert Medical School of Brown University and The Miriam Hospital, Providence, RI.
Ohad KottUrology Department, Minimally Invasive Urology Institute, Warren Alpert Medical School of Brown University and The Miriam Hospital, Providence, RI.
Anna MoshnikovaPhysics Department, University of Rhode Island, Kingston, RI.
Catrina Mueller-LeonhardUrology Department, Minimally Invasive Urology Institute, Warren Alpert Medical School of Brown University and The Miriam Hospital, Providence, RI.
Boris GershmanUrology Department, Minimally Invasive Urology Institute, Warren Alpert Medical School of Brown University and The Miriam Hospital, Providence, RI.
Oleg A AndreevPhysics Department, University of Rhode Island, Kingston, RI.
Yana K ReshetnyakPhysics Department, University of Rhode Island, Kingston, RI.
Ali AminDepartment of Pathology & Laboratory Medicine, The Warren Alpert Medical School of Brown University and The Miriam Hospital, Providence, RI.
Dragan GolijaninUrology Department, Minimally Invasive Urology Institute, Warren Alpert Medical School of Brown University and The Miriam Hospital, Providence, RI. Electronic address: Dragan.Golijanin@lifespan.org.

Funding

TM INTERACTIONS IN MEMBRANE PROTEIN FOLDING AND FUNCTIONR01GM073857 · NIGMS · YALE UNIVERSITY · PI ANDREEV, OLEG A, ENGELMAN, DONALD M. · 2006 to 2023
$8.4M
pHLIP Nanotechnology Platform for Cancer Imaging and TherapyR01CA133890 · NCI · UNIVERSITY OF RHODE ISLAND · PI ANDREEV, OLEG A, ENGELMAN, DONALD M. · 2008 to 2012
$3.8M
NCI NIH HHS R01 CA133890NIGMS NIH HHS R01 GM073857
6 · The paper itself

Abstract

objectiveTo improve visualization of upper tract urothelial carcinomas. Previous studies using the novel pH low insertion peptide (pHLIP) variant 3 (Var3) conjugated to indocyanine green (ICG) have demonstrated high sensitivity and specificity for imaging of bladder urothelial carcinoma. Here, we describe a novel approach for the imaging of upper tract urothelial carcinomas using ICG-Var3 pHLIP.

methodsTwelve ex-vivo upper urinary tract specimens were irrigated with ICG-Var 3 pHLIP for 15 minutes and then examined using a white light laparoscopic camera followed by near infrared fluorescent (NIRF) imaging using a Stryker 1588 AIM imaging system. Standard histopathologic evaluation was performed and findings were correlated with white light and ICG-Var3 NIRF imaging. One patient who underwent radical nephrectomy for renal cell carcinoma was used as a negative control.

resultsNineteen lesions were identified on histopathologic evaluation in 10 patients, including 82% high-grade urothelial carcinoma and 18% low-grade urothelial carcinoma. Nineteen (100%) malignant lesions were identified using NIRF imaging, while 15 (78.9%) lesions were identified using conventional white light examination. The sensitivity of ICG-Var3 pHLIP NIRF imaging was 100% compared to 78.9% white light examination. Both modalities are 100% specific. Benign collecting systems and ureters did not show uptake of the pHLIP construct.

conclusionIn this feasibility study, the ICG-Var3 pHLIP imaging agent demonstrated superior diagnostic performance compared to conventional white light examination. While additional studies are required for validation and in-vivo translation, pHLIP-based imaging represents a promising tool to improve the evaluation and management of upper tract urothelial carcinoma.

Indexed as

AgedCarcinoma, Renal CellColoring AgentsFeasibility StudiesFemaleHumansIndocyanine GreenIn Vitro TechniquesKidney NeoplasmsMaleMembrane ProteinsMolecular ImagingOptical ImagingPredictive Value of TestsSensitivity and SpecificityTumor MicroenvironmentColoring AgentsIndocyanine GreenMembrane ProteinspHLIP protein

Identifiers

PMID30659902
PMCPMC8882055

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.